Critical Insights From Viridian Therapeutics Analyst Ratings: What You Need To Know
Portfolio Pulse from Benzinga Insights
Viridian Therapeutics (NASDAQ:VRDN) has received varied analyst ratings over the past three months, with a majority being bullish. The average 12-month price target has increased slightly to $34.0. Analysts have maintained or adjusted their ratings and price targets, reflecting their views on the company's market position and financial performance. Despite challenges in revenue growth and profitability, Viridian's debt management is sound.
September 10, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Viridian Therapeutics has received mostly bullish analyst ratings, with an average price target increase to $34.0. Analysts have maintained or adjusted their ratings, indicating a positive outlook despite financial challenges.
The majority of analysts have given bullish ratings to Viridian Therapeutics, with a slight increase in the average price target. This suggests a positive short-term outlook for the stock. Despite financial challenges, the maintained and raised ratings indicate confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100